Journal
JOURNAL OF ADDICTIVE DISEASES
Volume 27, Issue 1, Pages 13-23Publisher
HAWORTH PRESS INC
DOI: 10.1300/J069v27n01_02
Keywords
Zyban; bupropion hydrochloride; cocaine dependence; randomized controlled trial
Categories
Funding
- NATIONAL INSTITUTE ON DRUG ABUSE [P50DA012755] Funding Source: NIH RePORTER
- NIDA NIH HHS [P50 DA 12755] Funding Source: Medline
Ask authors/readers for more resources
Bupropion hydrochloride is a dopamine and norepinephrine reuptake inhibitor which may be an effective treatment for cocaine dependence due to its ability to reverse deficits in dopaminergic functioning that occur in chronic cocaine users. We performed a randomized, double-blind, placebo controlled trial comparing outpatient treatment with bupropion (N = 37) and placebo (N = 33) in combination with standard cognitive behavioral therapy. There were no statistically significant differences between bupropion and placebo in treatment outcomes, including aggregate measures of urine drug screen results (Joint Probability Index at 16 weeks: 0.43 for bupropion and 0.38 for placebo), treatment retention, cocaine craving ratings, and assessments of depressive symptoms. The failure to find an effect for bupropion relative to placebo, when combined with standard cognitive behavioral therapy, dampens enthusiasm for future development of bupropion as a cocaine pharmacotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available